Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ECE1 | P42892 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.36 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.36 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 5/20 | 0.36 |
| ▸ | CA12 | O43570 | 4/20 | 0.36 |
| ▸ | CA1 | P00915 | 4/20 | 0.36 |
| ▸ | CA4 | P22748 | 4/20 | 0.36 |
| ▸ | CA9 | Q16790 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15697632 | 1.00 | SMN1; SMN2 (0.40) | SMN1; SMN2MEN1KMT2AECE1HDAC3 | |
| SCHEMBL16644687 | 1.00 | SMN1; SMN2 (0.40) | SMN1; SMN2MEN1KMT2AECE1HDAC3 | |
| SCHEMBL29603294 | 1.00 | SMN1; SMN2 (0.40) | SMN1; SMN2MEN1KMT2AECE1HDAC3 | |
| SCHEMBL15669304 | 1.00 | SMN1; SMN2 (0.40) | SMN1; SMN2MEN1KMT2AECE1HDAC3 | |
| SCHEMBL3710469 | 1.00 | SMN1; SMN2 (0.40) | SMN1; SMN2MEN1KMT2AECE1HDAC3 | |
| SCHEMBL14005135 | 0.89 | MEN1 (0.41) | SMN1; SMN2MEN1KMT2AHDAC3HDAC4 | |
| SCHEMBL7547013 | 0.88 | MEN1 (0.47) | SMN1; SMN2MEN1KMT2AHDAC3HDAC4 | |
| SCHEMBL3706509 | 0.88 | HDAC3 (0.43) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL20327919 | 0.87 | SMN1; SMN2 (0.39) | SMN1; SMN2MEN1KMT2AHDAC3HDAC4 | |
| SCHEMBL24117783 | 0.86 | ECE1 (0.50) | SMN1; SMN2MEN1KMT2AECE1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12059472-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-13 | — | — | US | disclosed |
| US-20230338559-A1 | ANTIBODY DRUG CONJUGATES (ADCS) HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-10-26 | — | — | US | disclosed |
| US-20230338559-A1 | ANTIBODY DRUG CONJUGATES (ADCS) HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-10-26 | — | — | US | disclosed |
| US-20230338559-A1 | ANTIBODY DRUG CONJUGATES (ADCS) HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-10-26 | — | — | US | disclosed |
| CN-116327974-A | Antibody-drug-conjugates (ADCs) with enzymatically cleavable groups | 拜耳制药股份公司 | 2023-06-27 | — | — | CN | disclosed |
| US-11660351-B2 | Antibody drug conjugates (ADCs) having enzymatically cleavable groups | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-30 | — | — | US | disclosed |
| US-11660351-B2 | Antibody drug conjugates (ADCs) having enzymatically cleavable groups | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-30 | — | — | US | disclosed |
| US-11660351-B2 | Antibody drug conjugates (ADCs) having enzymatically cleavable groups | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-30 | — | — | US | disclosed |
| CN-110312534-B | Antibody-drug-conjugates (ADC) with enzymatically cleavable groups | 拜耳制药股份公司 | 2023-04-04 | — | — | CN | disclosed |
| US-20220016258-A1 | ANTIBODY DRUG CONJUGATES (ADCS) HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-01-20 | — | — | US | disclosed |
| US-20190328897-A1 | ANTIBODY DRUG CONJUGATES (ADCS) HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-31 | — | — | US | disclosed |
| EP-3558388-A1 | ANTIBODY DRUG CONJUGATES (ADCS) HAVING ENZYMATICALLY CLEAVABLE GROUPS | Bayer Pharma Aktiengesellschaft (DE) | 2019-10-30 | — | — | EP | disclosed |
| EP-3558386-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | Bayer Aktiengesellschaft (DE) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018114798-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER AKTIENGESELLSCHAFT (DE) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018114578-A1 | ANTIBODY DRUG CONJUGATES (ADCS) HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018114578-A1 | ANTIBODY DRUG CONJUGATES (ADCS) HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-28 | — | — | WO | disclosed |
| EP-2448929-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-05-09 | — | — | EP | disclosed |
| EP-2398483-A1 | OXYNTOMODULIN ANALOGS | Merck Sharp & Dohme Corp. (US) | 2011-12-28 | — | — | EP | disclosed |
| WO-2011001052-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-06 | — | — | WO | disclosed |
| WO-2010096142-A1 | OXYNTOMODULIN ANALOGS | MERCK SHARP & DOHME, CORP. (US) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12059472-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | LGMN, BUB1B, KIF15 | SMN1; SMN2 1796/4885MEN1 1456/4885KMT2A 2874/4885 |
| US-20190328897-A1 | ANTIBODY DRUG CONJUGATES (ADCS) HAVING ENZYMATICALLY CLEAVABLE GROUPS | VCAM1, FCGR1A, DNPEP | SMN1; SMN2 3632/4885MEN1 1104/4885KMT2A 1466/4885 |
| US-20220016258-A1 | ANTIBODY DRUG CONJUGATES (ADCS) HAVING ENZYMATICALLY CLEAVABLE GROUPS | VCAM1, FCGR1A, DNPEP | SMN1; SMN2 3632/4885MEN1 1104/4885KMT2A 1466/4885 |
| US-20230338559-A1 | ANTIBODY DRUG CONJUGATES (ADCS) HAVING ENZYMATICALLY CLEAVABLE GROUPS | VCAM1, FCGR1A, DNPEP | SMN1; SMN2 3632/4885MEN1 1104/4885KMT2A 1466/4885 |
| US-11660351-B2 | Antibody drug conjugates (ADCs) having enzymatically cleavable groups | VCAM1, FCGR1A, DNPEP | SMN1; SMN2 3632/4885MEN1 1104/4885KMT2A 1466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.